FinTechFunding

Immutep: Shares positive data from phase 2b AIPAC trial

Immutep Shares positive data from phase 2b AIPAC trial

  • Immutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase IIb AIPAC trial
  • The trial evaluated efti combined with paclitaxel chemotherapy compared to a placebo group in 227 patients with HER2-negative/HR-positive metastatic breast cancer
  • IMM says the higher immune response in efti patients compared to placebo patients confirms efti is activating the immune system and improving overall survival
  • The company is a globally active biotechnology company that is a leader in developing LAG-3 related immunotherapeutic products
  • The company is trading 7.58 per cent higher at 35.5 cents
Previous article
Intigriti: Raises Over €21.13M in Series B Funding
Next article
Elixir Energy: Completes Tim-2 well in Mongolia
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Solana Foundation Launches Financial Developer Platform

Enhancing tools for developers in the blockchain finance space.Highlights: Solana Foundation introduces a new financial developer platform.The platform...
FinTech

Spade Raises $40M to Strengthen Data and AI Platform

The funding will expand Spade's capabilities in data analytics and AI.Highlights: Spade has raised $40 million in Series...
FinTech

New York State Mandates Stores to Accept Cash Payments

New legislation aims to protect cash transactions across the state.Highlights: New law requires New York stores to accept...
FinTech

PRA Issues £2 Million Penalty to Bank of London for Integrity Failures

Regulatory body penalizes the bank due to integrity shortcomings.Highlights: PRA fines Bank of London £2 million for integrity...